PTC Therapeutics Inc (PTCT)

7.98
NASDAQ : Health Care
Prev Close 7.98
Day Low/High 0.00 / 0.00
52 Wk Low/High 5.27 / 42.00
Avg Volume 1.04M
Exchange NASDAQ
Shares Outstanding 34.25M
Market Cap 283.91M
EPS -5.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Strong On High Volume: PTC Therapeutics (PTCT)

Strong On High Volume: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.

Strong On High Relative Volume: PTC Therapeutics (PTCT)

Strong On High Relative Volume: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

NHS England Enables Access To Translarna™ ¿ (ataluren) For Patients With Nonsense Mutation Duchenne Muscular Dystrophy

NHS England Enables Access To Translarna™ ¿ (ataluren) For Patients With Nonsense Mutation Duchenne Muscular Dystrophy

--Important decision allows reimbursed access to Translarna, the first approved therapy to treat the underlying cause of Duchenne muscular dystrophy--

Commit To Purchase PTC Therapeutics At $5, Earn 30% Using Options

Commit To Purchase PTC Therapeutics At $5, Earn 30% Using Options

Investors considering a purchase of PTC Therapeutics Inc shares, but tentative about paying the going market price of $6.65/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.50.

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

PTC Therapeutics (PTCT) Weak On High Volume

PTC Therapeutics (PTCT) Weak On High Volume

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a weak on high relative volume candidate

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

GPM Reminds Investors Of The May 2 Deadline In The Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The May 2 Deadline In The Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming May 2, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased PTC Therapeutics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of PTC Therapeutics, Inc.

EXPANDED CLASS PERIOD: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm

EXPANDED CLASS PERIOD: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against PTC Therapeutics, Inc.

INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Class Action Involving PTC Therapeutics, Inc. And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT

INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Class Action Involving PTC Therapeutics, Inc. And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PTC Therapeutics, Inc.

Today's Dead Cat Bounce Stock Is PTC Therapeutics (PTCT)

Today's Dead Cat Bounce Stock Is PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Perilous Reversal Stock: PTC Therapeutics (PTCT)

Perilous Reversal Stock: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "perilous reversal" (up big yesterday but down big today) candidate

Why PTC Therapeutics (PTCT) Stock Is Spiking Today

Why PTC Therapeutics (PTCT) Stock Is Spiking Today

PTC Therapeutics (PTCT) stock is skyrocketing this afternoon after a U.K. regulator recommended its drug for a deadly muscle disease.

NICE Recommends Translarna™ (ataluren) For The Treatment Of Patients With Nonsense Mutation Duchenne Muscular Dystrophy In England

NICE Recommends Translarna™ (ataluren) For The Treatment Of Patients With Nonsense Mutation Duchenne Muscular Dystrophy In England

-Positive Recommendation Enables Reimbursed Patient Access to First Approved Therapy to Treat Underlying Cause of Devastating Rare Disease-

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of PTC Therapeutics, Inc.